Cosmo Reports Phase 2 Study Met Primary Endpoint in Colitis
Cosmo announced topline Phase 2 results for rifamycin 1% topically acting gel in distal ulcerative colitis and ulcerative proctitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.